Amgen, Kleiner Perkins Spin-Out Atara Sails Into The Spotlight
This article was originally published in The Pink Sheet Daily
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.
You may also be interested in...
Series A Financing For Annovation Includes Potential Buyout By TMC
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.